Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE : Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

MLA

Jahn, Ulrika, et al. Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE : Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1248716502&authtype=sso&custid=ns315887.

APA

Jahn, U., Ilan, E., Sandström, M., Lubberink, M., Garske-Román, U., & Sundin, A. (2021). Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE : Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms.

Chicago

Jahn, Ulrika, Ezgi Ilan, Mattias Sandström, Mark Lubberink, Ulrike Garske-Román, and Anders Sundin. 2021. “Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE : Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1248716502&authtype=sso&custid=ns315887.